CXCL13 and neoplasm: Notably, CD4+ T cells with B cell-helper features, including high expression of PD-1, ICOS, and CXCL13, are enriched in multiple solid tumors and in murine tumor model, and these cells are preferentially expanded by anti-CTLA4 but not anti-PD-1 therapy [118–120].